ImageneBio annual stock-based compensation
2020
2021
2022
2023
2024
2025
ImageneBio Stock-Based Compensation Growth & History (IMA)
ImageneBio's stock-based compensation was $15.4M for fiscal 2025.
View full ImageneBio company overviewImageneBio annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $15.4M | $15.4M | — |
| 2024 | 2024-12-31 | $0 | −$7.6M | — |
| 2023 | 2023-12-31 | $7.6M | $107,000 | +1.42% |
| 2022 | 2022-12-31 | $7.5M | $2.3M | +45.35% |
| 2021 | 2021-12-31 | $5.2M | $3.4M | +188.09% |
| 2020 | 2020-12-31 | $1.8M | — | — |
ImageneBio quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $911,000 | $911,000 | — |
| Q1 2026 | 2026-03-31 | $876,000 | $819,000 | +1436.84% |
| Q4 2025 | 2025-12-31 | $51,000 | — | — |
| Q3 2025 | 2025-09-30 | $15.3M | $14.3M | +1402.75% |
| Q2 2025 · Jul 25 | 2025-07-25 | $14.0M | — | — |
| Q2 2025 · Jun 30 | 2025-06-30 | $0 | −$1.3M | — |
| Q1 2025 | 2025-03-31 | $57,000 | −$1.9M | −97.15% |
| Q3 2024 | 2024-09-30 | $1.0M | −$981,000 | −49.10% |
| Q2 2024 | 2024-06-30 | $1.3M | −$600,000 | −31.93% |
| Q1 2024 | 2024-03-31 | $2.0M | $1,000 | +0.05% |
| Q4 2023 | 2023-12-31 | $1.8M | −$104,000 | −5.59% |
| Q3 2023 | 2023-09-30 | $2.0M | $187,000 | +10.33% |
| Q2 2023 | 2023-06-30 | $1.9M | −$76,000 | −3.89% |
| Q1 2023 | 2023-03-31 | $2.0M | $100,000 | +5.26% |
| Q4 2022 | 2022-12-31 | $1.9M | $278,000 | +17.58% |
| Q3 2022 | 2022-09-30 | $1.8M | $362,000 | +24.98% |
| Q2 2022 | 2022-06-30 | $2.0M | $693,000 | +54.91% |
| Q1 2022 | 2022-03-31 | $1.9M | $1.0M | +114.69% |
| Q4 2021 | 2021-12-31 | $1.6M | $931,000 | +143.23% |
| Q3 2021 | 2021-09-30 | $1.4M | $1.0M | +246.65% |
| Q2 2021 | 2021-06-30 | $1.3M | $908,000 | +256.50% |
| Q1 2021 | 2021-03-31 | $885,000 | $510,000 | +136.00% |
| Q4 2020 | 2020-12-31 | $650,000 | — | — |
| Q3 2020 | 2020-09-30 | $418,000 | — | — |
| Q2 2020 | 2020-06-30 | $354,000 | — | — |
| Q1 2020 | 2020-03-31 | $375,000 | — | — |
ImageneBio stock-based compensation trends
Over the last five fiscal years, ImageneBio's stock-based compensation increased from $1.8M to $15.4M, a change of $13.6M. The latest reported quarter, Q2 2026, shows $911,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ImageneBio source filings ↗